

Name of Journal: *World Journal of Gastrointestinal Oncology*

Manuscript NO: 56283

Manuscript Type: ORIGINAL ARTICLE

Basic Study

Interleukin-1 receptor antagonist enhances the chemosensitivity of fluorouracil in the treatment of Kras mutated colon cancer

Yan Y *et al.* IL-1RA inhibit colon cancer

Yan Yan, Hong-Wei Lin, Zhuo-Nan Zhuang, Ming Li, Sen Guo

Abstract

BACKGROUND

Match Overview

There are no matching sources for this report.



ALL

IMAGES

VIDEOS

7,090 Results

Any time ▼

Chemoresistance and targeted therapies in ovarian and ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5354810>

Jan 17, 2017 · **Estrogen receptor antagonists** . Fulvestrant (Faslodex), is a novel estrogen receptor (ER) antagonist providing increased **proteasomal degradation** of its target. A phase II trial tested this compound in advanced **endometrial cancer** with 31 patients (**estrogen receptor positive**) and 22 patients (**estrogen receptor negative**).

Cited by: 30

Author: Kevin Brasseur, Nicolas Gévry, Eric Ass...

Publish Year: 2017

Perspectives in the treatment of pancreatic adenocarcinoma

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4541382>

Aug 21, 2015 · **KRAS** activation is essential for pancreatic **cancer** cell survival. Activated mutant **KRAS** signals primarily through the PI3K, p38, JNK and FAK signaling pathways. It also involves the epidermal growth factor **receptor** (EGFR), BCL-XL and the nuclear factor κB[17-20].

Cited by: 101

Author: Angel Cid-Arregui, Victoria Juarez

Publish Year: 2015

Advances in targeted and immunobased therapies for ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4821380>

Mar 31, 2016 · Treatment of **colon cancer cell lines** with a **γ-secretase inhibitor** renders the **cell** lines more sensitive to **chemotherapeutic treatments**, such as with oxaliplatin, **5-fluorouracil**, or SN-38 (irinotecan).148 Whether this in **vitro study** can be extrapolated to in vivo is still unknown.

Cited by: 18

Author: Heng Fong Seow, Wai Kien Yip, Theodo...

Publish Year: 2016

[PDF] Fluorouracil and bevacizumab plus anakinra for patients ...

<https://www.tandfonline.com/doi/pdf/10.1080/2162402X.2018.1474319>

IL-1 β inhibition using canakinumab could prevent lung **cancer** growth,7 and another recent trial has



ALL

IMAGES

VIDEOS

2,780 Results

Any time ▾

Interleukin-1 β and Cancer

<https://www.mdpi.com/2072-6694/12/7/1791/pdf> ▾

an amplification loop between IL-1 β and mutated-KRAS seems to increase cancer progression and drug resistance. ... DCs to produce IL-1 β and enhance inhibition of colon cancer growth. ... repression of the secreted interleukin-1 receptor antagonist. *Oncogene* 2014, 34, 2493–2504.

Cancers | Free Full-Text | Interleukin-1 β and Cancer | HTML

<https://www.mdpi.com/2072-6694/12/7/1791/htm> ▾

Thus, an amplification loop between IL-1 β and mutated-KRAS seems to increase cancer progression and drug resistance. Expression of mutated BRAF (v-raf murine sarcoma viral oncogene homolog B1) V600E mutation induces the transcription of IL1A and IL1B in papillary thyroid carcinoma cells, melanocytes, and melanoma cell lines and this induction ...

Rationale and Means to Target Pro-Inflammatory Interleukin ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3817732>

Aug 06, 2013 · For instance, inflammatory bowel disease is associated with an increased risk of colon cancer development [3,4] and chronic prostatitis has been linked to the development of prostate cancer [5,6]. Furthermore, regular long-term use of anti-inflammatory drugs (e.g., aspirin) is known to decrease the risk of several cancer types [7,8].

Cited by: 102

Author: Laura M. Campbell, Pamela J. Maxwell, ...

Publish Year: 2013

(PDF) Targeting the interleukin-1 pathway in patients with ...

<https://www.researchgate.net/publication/316805059...>

Targeting the interleukin-1 pathway in patients with hematological disorders Article (PDF Available) in *Blood* 129(24):blood-2016-12-754994 · May 2017 with 92 Reads How we measure 'reads'

Molecular predictive and prognostic markers in colon cancer

<https://www.sciencedirect.com/science/article/pii/S0305737210000575>

Introduction. Colorectal cancer is the second most common cause of cancer related death in the western societies. 1 Colorectal cancer is a result of an accumulation of genetic and epigenetic alterations causing disorders in cell growth, differentiation and apoptosis resulting in transformation of normal colonic epithelium to colon adenocarcinoma. The most important etiological factor to date ...



ALL

IMAGES

VIDEOS

MAPS

NEWS

SHOPPING

2,800 Results

Any time ▾

[Cancers | Free Full-Text | Interleukin-1 \$\beta\$ and Cancer | HTML](https://www.mdpi.com/2072-6694/12/7/1791/htm)

<https://www.mdpi.com/2072-6694/12/7/1791/htm>

Thus, an amplification loop between IL-1 β and **mutated-KRAS** seems to increase **cancer** progression and drug resistance. Expression of **mutated** BRAF (v-raf murine sarcoma viral oncogene homolog B1) V600E mutation induces the transcription of IL1A and IL1B in papillary thyroid carcinoma cells, melanocytes, and melanoma cell lines and this induction ...

[Rationale and Means to Target Pro-Inflammatory Interleukin ...](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3817732)

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3817732>

Aug 06, 2013 · For instance, inflammatory bowel disease is associated with an increased risk of **colon cancer** development [3,4] and chronic prostatitis has been linked to the development of prostate **cancer** [5,6]. Furthermore, regular long-term use of anti-inflammatory drugs (e.g., aspirin) is known to decrease the risk of several **cancer** types [7,8].

Cited by: 108

Author: Laura M Campbell, Pamela J Maxwell, D...

Publish Year: 2013

[Exogenous interleukin-1 \$\alpha\$ signaling negatively impacts ...](https://www.sciencedirect.com/science/article/pii/S1043466618304733)

<https://www.sciencedirect.com/science/article/pii/S1043466618304733>

Cell **treatment** schedule is shown in Fig. 1. Recombinant human interleukin-1 α and **interleukin-1 receptor antagonist** (rhIL-1 α and rhIL-1Ra, respectively; R&D Systems) were added to culture medium at appropriate concentrations right after seeding of the cells. 2.5 ng of recombinant protein per milliliter of cultivation medium was used, if not specified otherwise. rhIL-1Ra was used as a negative ...

Cited by: 1

Author: Pranas Grigaitis, Violeta Jonusiene, Vilm...

Publish Year: 2019

[Interleukin-1 and Related Cytokines in the Regulation of ...](https://www.researchgate.net/publication/340871610...)

<https://www.researchgate.net/publication/340871610...>

Interleukin-1 (IL-1) is a key mediator of inflammation and immunity. Naturally occurring IL-1 **Receptor antagonist** (IL-1Ra) binds and blocks the IL-1 **Receptor-1** (IL-1R1), preventing ...